The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Open accessAbstract
BACKGROUND: Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are rare and frequently lethal tumors that so far have not been subjected to comprehensive genetic characterization. METHODS: We performed next-generation sequencing of 341 cancer genes from 117 patient-derived PDTCs and ATCs and analyzed the transcriptome of a representative subset of 37 tumors. Results were analyzed in the context of The Cancer Genome Atlas study (TCGA study) of papillary thyroid cancers (PTC). RESULTS: Compared to PDTCs, ATCs had a greater mutation burden, including a higher frequency of mutations in TP53, TERT promoter, PI3K/AKT/mTOR pathway effectors, SWI/SNF subunits, and histone methyltransferases. BRAF and RAS were the predominant drivers and dictated distinct tropism for nodal versus distant metastases in PDTC. RAS and BRAF sharply distinguished between PDTCs defined by the Turin (PDTC-Turin) versus MSKCC (PDTC-MSK) criteria, respectively. Mutations of EIF1AX, a component of the translational preinitiation complex, were markedly enriched in PDTCs and ATCs and had a striking pattern of co-occurrence with RAS mutations. While TERT promoter mutations were rare and subclonal in PTCs, they were clonal and highly prevalent in advanced cancers. Application of the TCGA-derived BRAF-RAS score (a measure of MAPK transcriptional output) revealed a preserved relationship with BRAF/RAS mutation in PDTCs, whereas ATCs were BRAF-like irrespective of driver mutation. CONCLUSIONS: These data support a model of tumorigenesis whereby PDTCs and ATCs arise from well-differentiated tumors through the accumulation of key additional genetic abnormalities, many of which have prognostic and possible therapeutic relevance. The widespread genomic disruptions in ATC compared with PDTC underscore their greater virulence and higher mortality. FUNDING: This work was supported in part by NIH grants CA50706, CA72597, P50-CA72012, P30-CA008748, and 5T32-CA160001; the Lefkovsky Family Foundation; the Society of Memorial Sloan Kettering; the Byrne fund; and Cycle for Survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationGene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Self-citationMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationA Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z., Irizarry, R. A., Gentleman, R., Martinez-Murillo, F., & Spencer, F. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,716
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz400 · Cited by 1,200
Overview of the 2022 WHO Classification of Thyroid Neoplasms
Baloch, Z. W., Asa, S. L., Barletta, J. A., Ghossein, R. A., Juhlin, C. C., Jung, C. K., LiVolsi, V. A., Papotti, M. G., Sobrinho-Simões, M., Tallini, G., et al. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09707-3 · Cited by 1,158
Self-citationBiologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
Self-citationSubbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
Wirth, L. J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., Patel, J., Leboulleux, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005651 · Cited by 790
Bible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Boucai, L., Zafereo, M., & Cabanillas, M. E. (2024) · JAMA · doi:10.1001/jama.2023.26348 · Cited by 701
Self-citationChen, D. W., Lang, B. H. H., McLeod, D. S. A., Newbold, K., & Haymart, M. R. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00020-x · Cited by 590
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 571
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Patel, K. N., Yip, L., Lubitz, C. C., Grubbs, E. G., Miller, B. S., Shen, W., Angelos, P., Chen, H., Doherty, G. M., Fahey, T. J., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003580 · Cited by 541
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Pozdeyev, N., Gay, L. M., Sokol, E. S., Hartmaier, R., Deaver, K. E., Davis, S., French, J. D., Borre, P. V., LaBarbera, D. V., Tan, A.-C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0373 · Cited by 533
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Molinaro, E., Romei, C., Biagini, A., Sabini, E., Agate, L., Mazzeo, S., Materazzi, G., Sellari-Franceschini, S., Ribechini, A., Torregrossa, L., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.76 · Cited by 483
Update on Fundamental Mechanisms of Thyroid Cancer
Prete, A., Borges de Souza, P., Censi, S., Muzza, M., Nucci, N., & Sponziello, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00102 · Cited by 471
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules
Nikiforova, M. N., Mercurio, S., Wald, A. I., Barbi de Moura, M., Callenberg, K., Santana‐Santos, L., Gooding, W. E., Yip, L., Ferris, R. L., & Nikiforov, Y. E. (2018) · Cancer · doi:10.1002/cncr.31245 · Cited by 396
PD-1 Blockade in Anaplastic Thyroid Carcinoma
Capdevila, J., Wirth, L. J., Ernst, T., Ponce Aix, S., Lin, C.-C., Ramlau, R., Butler, M. O., Delord, J.-P., Gelderblom, H., Ascierto, P. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02727 · Cited by 353
Clinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, V., Baik, C., & Kirkwood, J. M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.009 · Cited by 344
Current practice in patients with differentiated thyroid cancer
Schlumberger, M., & Leboulleux, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00448-z · Cited by 342
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Cabanillas, M. E., Ryder, M., & Jimenez, C. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00007 · Cited by 335
Xu, B., Fuchs, T., Dogan, S., Landa, I., Katabi, N., Fagin, J. A., Tuttle, R. M., Sherman, E., Gill, A. J., & Ghossein, R. (2020) · Thyroid · doi:10.1089/thy.2020.0086 · Cited by 301
Self-citationSolomon, B. J., Tan, L., Lin, J. J., Wong, S. Q., Hollizeck, S., Ebata, K., Tuch, B. B., Yoda, S., Gainor, J. F., Sequist, L. V., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.006 · Cited by 289
Fugazzola, L., Elisei, R., Fuhrer, D., Jarzab, B., Leboulleux, S., Newbold, K., & Smit, J. (2019) · European Thyroid Journal · doi:10.1159/000502229 · Cited by 285
Ganly, I., Makarov, V., Deraje, S., Dong, Y., Reznik, E., Seshan, V., Nanjangud, G., Eng, S., Bose, P., Kuo, F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.002 · Cited by 283
Self-citationYoo, S.-K., Song, Y. S., Lee, E. K., Hwang, J., Kim, H. H., Jung, G., Kim, Y. A., Kim, S.-J., Cho, S. W., Won, J.-K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10680-5 · Cited by 268
Gopal, R. K., Kübler, K., Calvo, S. E., Polak, P., Livitz, D., Rosebrock, D., Sadow, P. M., Campbell, B., Donovan, S. E., Amin, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.013 · Cited by 263
New Therapies for Advanced Thyroid Cancer
Laha, D., Nilubol, N., & Boufraqech, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00082 · Cited by 261
Körber, V., Yang, J., Barah, P., Wu, Y., Stichel, D., Gu, Z., Fletcher, M. N. C., Jones, D., Hentschel, B., Lamszus, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.007 · Cited by 260
Dierks, C., Seufert, J., Aumann, K., Ruf, J., Klein, C., Kiefer, S., Rassner, M., Boerries, M., Zielke, A., la Rosee, P., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0322 · Cited by 254
Wang, J. R., Zafereo, M. E., Dadu, R., Ferrarotto, R., Busaidy, N. L., Lu, C., Ahmed, S., Gule-Monroe, M. K., Williams, M. D., Sturgis, E. M., et al. (2019) · Thyroid® · doi:10.1089/thy.2019.0133 · Cited by 230
Shonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., et al. (2022) · Head & Neck · doi:10.1002/hed.27025 · Cited by 117
Self-citationEIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC
Krishnamoorthy, G. P., Davidson, N. R., Leach, S. D., Zhao, Z., Lowe, S. W., Lee, G., Landa, I., Nagarajah, J., Saqcena, M., Singh, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0606 · Cited by 94
Self-citation
Metadata
- Authors
- Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., Schultz, N., Berger, M. F., Sander, C., Taylor, B. S., Ghossein, R., Ganly, I., & Fagin, J. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2016-02-15
- Volume
- 126
- Issue
- 3
- Pages
- 1052-1066
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2279570938
- Cited by
- 1,284
- References
- 62
- FWCI
- 96.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.